Allergan plc

Most Recent

  • uploads///Graph
    Miscellaneous

    Teva Can Benefit by Acquiring Allergan Generics

    The combined Teva–Allergan generics entity should have approximately 320 Abbreviated New Drug Applications (or ANDAs), including 110 first-to-file ANDAs (or FTF) in the US.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Biogen’s Experimental Alzheimer Therapy: Limited 2Q15 Success

    On July 22, 2015, Biogen (BIIB) released data from a Phase 1b study, also called the PRIME Study, that looked at the effectiveness of its investigational Alzheimer’s drug, BIIB037.

    By Margaret Patrick
  • uploads///teva loss
    Company & Industry Overviews

    Teva Pharmaceutical: Earnings Trends and Recent Developments

    Teva Pharmaceutical’s net income and diluted EPS in the first nine months of 2018 amounted to $541.0 million and $0.53, respectively.

    By Daniel Collins
  • Healthcare

    Farallon Capital adds a new position in Covidien

    Ireland-based Covidien is a global healthcare leader that offers innovative medical technology solutions and patient care products to providers.

    By Patricia Garner
  • uploads///Chart
    Company & Industry Overviews

    What Did AGN’s US Medical Aesthetics Segment Contribute in 1Q16?

    Allergan’s US medical aesthetics segment includes facial aesthetics, medical dermatology products, and a wide range of silicone and saline breast implants.

    By Mike Benson
  • Consumer

    Farallon Capital exits its position in Time Warner Cable

    In February, Comcast agreed to buy Time Warner Cable for ~$45.2 billion. This deal will create the largest cable provider in the U.S.

    By Patricia Garner
  • uploads///PAH
    Basic Materials

    Why Pershing Square initiated a position in Platform Specialty Products

    Pershing Square disclosed a new position in Platform Specialty Products (PAH) that accounts for 7.58% of Pershing Square’s 1Q14 portfolio.

    By Samantha Nielson
  • uploads///Sucampo Revenue Growth
    Company & Industry Overviews

    Key Risks Facing Sucampo Pharmaceuticals in 2017

    Sucampo has taken on a significant level of debt. Its outstanding debt is ~$300 million. Its interest expense has increased from $6.8 million in 2015 to $23.7 million in 2016.

    By Kenneth Smith
  • uploads///AGN PFE PFE basics
    Miscellaneous

    Allergan–Pfizer merger: What Does Pfizer Make besides Viagra?

    The Allergan–Pfizer merger will change Pfizer’s domicile to Dublin, Ireland, and allow them to gain access to overseas cash without a US repatriation tax.

    By Brent Nyitray, CFA, MBA
  • uploads///Graph
    Company & Industry Overviews

    This Space Presents a Market Opportunity for Valeant

    In Valeant’s 2Q16 earnings, Xifaxan reported a year-over-year (or YoY) increase in monthly prescriptions of about 28.0%.

    By Margaret Patrick
  • uploads///strensiq
    Earnings Report

    Inside Alexion’s Metabolic Drugs Kanuma and Strensiq

    In 1Q16, Strensiq added $33.2 million to Alexion Pharmaceuticals’ top line. Now the drug is in its initial launch phase in the US, Germany, and Japan.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    Allergan Boosts XLV Large-Caps with Positive 4Q15 Earnings

    Allergan (AGN) reported its 4Q15 earnings on February 22, 2016. It reported net revenue of $4.2 billion for 4Q15, an increase of 74% compared to $2.4 billion in 4Q14.

    By Peter Neil
  • uploads///attractive product profile
    Company & Industry Overviews

    What’s behind Biogen Buyout Rumors?

    Since early August 2016, there have been rumors of a likely buyout of Biogen (BIIB) by one of the many interested suitors in the biotechnology industry.

    By Sarah Collins
  • uploads///HME
    Basic Materials

    Why Ackman started a position in REIT Home Properties

    Pershing Square disclosed a new position in Home Properties Inc. (HME) that accounts for 0.34% of Pershing Square’s $8.3 billion 1Q14 portfolio.

    By Samantha Nielson
  • uploads///Price Movement in the VFINX and the SPY
    Company & Industry Overviews

    Why Did US Stock Indices Rise?

    Treasury yields fell across the yield curve last week after the US Department of Labor reported that the economy added fewer jobs in April.

    By Lynn Noah
  • uploads///MCO
    Financials

    Must-know: Eton Park sells stake in Moody’s

    Eton Park exited a position in Moody’s Corp (MCO) that accounted for 2.7% of the fund’s first quarter portfolio.

    By Samantha Nielson
  • uploads///Graph
    Company & Industry Overviews

    Entering Migraine Market Won’t Be Easy for Novartis, Amgen

    Novartis (NVS) and Amgen (AMGN) recently announced that the CGRP inhibitor therapy, AMG 334, reported positive results in a Phase 2 clinical trial as a therapy for preventing chronic migraine.

    By Margaret Patrick
  • uploads///Chart  EPS
    Miscellaneous

    Understanding Allergan’s Valuation after the 1Q17 Results

    On May 10, 2017, Allergan (AGN) was trading at a forward PE multiple of ~14.1x, as compared to the industry average of 11.9x.

    By Mike Benson
  • uploads///VRX
    Fund Managers

    Point72 Reduces Its Stake in Valeant Pharmaceuticals

    Point72 reduced its stake in Valeant Pharmaceuticals by selling 924,400 shares. It held 132,300 Valeant shares. Valeant accounted for 0.13% of the fund’s 4Q14 portfolio.

    By Diana Key
  • Consumer

    Farallon Capital raises its position in Safeway

    On March 6, 2014, grocery store operators Safeway and Albertsons announced a merger agreement valued at approximately $9 billion.

    By Patricia Garner
  • uploads///salix
    Company & Industry Overviews

    What Might Have Fueled Valeant’s Interest in Salix?

    The gastrointestinal (or GI) drug market in the United States is expected to grow at a CAGR of 5.0% over a five-year period from 2014 to 2019.

    By Jillian Dabney
  • uploads///hospital _
    Earnings Report

    Allergan’s 1Q18 Earnings: Analysts’ Estimates

    Allergan (AGN) plans to release its 1Q18 earnings on April 30. Wall Street expect AGN’s earnings per share to reach $3.36.

    By Mike Benson
  • uploads///article
    Macroeconomic Analysis

    ITHAX’s Top Holding Was Trading above Moving Averages

    Amazon was trading at 1.3%, 4.5%, and 33.1% above its 20-day, 50-day, and 200-day moving averages, respectively, as of December 28, 2015.

    By Seth Bennett
  • Healthcare

    Eton Park opens new position in AerCap Holdings

    Eton Park started a new position in AerCap Holdings (AER) that accounts for 1.39% of the fund’s second quarter portfolio.

    By Samantha Nielson
  • uploads///chart_ __ _cresemba
    Company & Industry Overviews

    Pfizer Has Received Commercial Rights for Cresemba in Europe

    On June 14, 2017, Pfizer (PFE) announced an agreement with Basilea Pharmaceutica for exclusive commercial rights for Cresemba in Europe.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Why Eli Lilly Expects 2Q17 Revenue Growth

    As per analysts’ estimates, Eli Lilly’s (LLY) revenues could rise ~3.6% to $5.6 billion in 2Q17.

    By Mike Benson
  • Consumer

    Farallon Capital establishes a new position in Hillshire Brands

    Hillshire reported fiscal 4Q14 net sales of $1.1 billion, up 10.7% in comparison to the corresponding period last year.

    By Patricia Garner
  • uploads///Chart
    Company & Industry Overviews

    What Are Analysts Estimating for Allergan Today?

    AGN’s analysts estimate EPS of $4.72 on revenues of $4.27 billion for 4Q17, which would be 10.5% higher YoY (year-over-year).

    By Mike Benson
  • uploads///Pershing
    Financials

    Pershing Square takes on Zoetis, adds to Canadian Pacific in 3Q14

    Activist hedge fund manager William Ackman’s Pershing Square Capital Holdings filed its third quarter 13F last month. The fund’s year-to-date returns as of October 31, 2014, net of fees, was 35.0%.

    By Samantha Nielson
  • uploads///aerial view of various medical pills pharmaceutical
    Company & Industry Overviews

    An Easier Way to Understand the Pharma Industry

    In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.

    By Sybil Prowse
  • uploads///AdobeStock_
    Company & Industry Overviews

    Bill Gross: Top Stock Picks with High Dividend Yields

    On October 18, CNBC reported Bill Gross top picks. His top stock picks were Annaly Capital (NLY), Invesco (IVZ) and Allergan (AGN).

    By Rabindra Samanta
  • uploads///HLF put options
    Consumer

    Limited risk of Herbalife stock price increase, Ackman believes

    Ackman believes there’s little chance of an Herbalife stock price increase and said Herbalife’s stock price is down almost 50%.

    By Samantha Nielson
  • uploads///abdfdfadcaeadbecbe
    Financials

    Carl Icahn Says Allergan Is Undervalued, Takes a Large Position

    “Allergan has a great pipeline,” said Icahn. For Icahn, this healthcare sector (XLV) firm’s stock appears to be undervalued.

    By Surbhi Jain
  • uploads///stock picture HJHQsQohM
    Consumer

    Wellington Management: Analyzing Its Top Holdings

    Wellington Management filed its 13F on Wednesday. Based on the filing, the market value of total publicly traded securities was around $443.45 billion.

    By Rabindra Samanta
  • uploads///business _
    Company & Industry Overviews

    AbbVie Announces Acquisition of Allergan: What You Should Know

    On June 25, AbbVie (ABBV) announced a definitive agreement to acquire Allergan (AGN) in a cash and stock transaction for a total consideration of $63 billion. The deal values Allergan at a 45% premium to its closing price on June 24. AbbVie aims to reduce excessive revenue exposure to Humira through this deal.

    By Margaret Patrick
  • uploads///molecule _
    Company & Industry Overviews

    What’s Pulling Down Allergan’s Share Price in 2019?

    On March 6, Allergan (AGN) issued a press release announcing the failure of its investigational therapy rapastinel to meet the primary and secondary end points in three pivotal trials evaluating it as an adjunctive therapy in combination with antidepressant therapy in major depressive disorder indications.

    By Margaret Patrick
  • uploads///bacteria _
    Company & Industry Overviews

    How Is Allergan’s Revenue Trending in 2019?

    In its first-quarter earnings investor presentation, Allergan (AGN) revised its 2019 revenue guidance upward from its previous estimate of $15.0 billion–$15.3 billion to $15.1 billion–$15.4 billion.

    By Margaret Patrick
  • uploads///analysis _
    Company & Industry Overviews

    AbbVie or Allergan: Which Is a Better Pick in June?

    AbbVie (ABBV) is down 14.69%, and Allergan (AGN) is down 13.41% in 2019 on a year-to-date basis. While concerns about the anticipated generic erosion of its flagship Humira franchise have proved to be a drag for AbbVie, Allergan is being increasingly criticized for a couple of reasons.

    By Margaret Patrick
  • uploads///Part
    Energy & Utilities

    Where’s the ‘Next Warren Buffett’ Placing His Bets?

    After Twenty-First Century Fox (FOX) (FOXA), Cheniere Energy (LNG) is Seth Klarman’s biggest bet.

    By Anuradha Garg
  • uploads///achievement _
    Consumer

    Why Twenty-First Century Fox Remains Seth Klarman’s Favorite Bet

    Seth Klarman’s portfolio value at the end of the fourth quarter was $11.5 billion.

    By Anuradha Garg
  • uploads///hypertension _
    Company & Industry Overviews

    What Analysts Are Recommending for Teva Pharmaceutical This Month

    On February 15, Teva Pharmaceutical (TEVA) closed at $17.98, 4.05% higher than its previous closing price.

    By Margaret Patrick
  • uploads///Teva pharma
    Company & Industry Overviews

    A Financial Overview of Teva Pharmaceutical in December

    In the first nine months of 2018, Teva Pharmaceutical’s net revenue fell 16% YoY (year-over-year) to $14.3 billion from $17.0 billion.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Teva Pharmaceutical Stock Rose More than ~8% on December 26

    On December 26, Teva Pharmaceutical (TEVA) stock closed at $15.82, a rise of ~8.43% from its close of $14.59 on December 24.

    By Daniel Collins
  • uploads///pills _
    Company & Industry Overviews

    Bausch’s Ultra Multifocal Contact Lenses Get FDA Approval

    On December 5, Bausch + Lomb announced that the FDA approved its Ultra multifocal contact lenses for patients with astigmatism.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    A Look at Celgene’s Revlimid Label Expansion Initiatives in 2018

    On October 23, 2018, Celgene issued a press release announcing favorable results from open-label Phase 2/3 trial, ECOG E3A06, evaluating Revlimid in the smoldering multiple myeloma (or MM) indication.

    By Margaret Patrick
  • uploads///bausch
    Company & Industry Overviews

    How Bausch Health’s Financials Look in November

    Bausch Health (BHC) generated revenues of $2.1 billion in the third quarter of this year compared to $2 billion in the third quarter of 2017.

    By Daniel Collins
  • uploads///dna _
    Earnings Report

    Allergan Beats EPS and Revenue Estimates: Q3 2018 Earnings

    Allergan (AGN) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for EPS and revenues, and it reported non-GAAP EPS of $4.25 on revenues of $3.91 billion.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Recommendations for Shire as of October 30

    Analysts’ estimates show that Shire (SHPG) stock has a potential to return ~15.8% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Amgen: Expect Nearly Flat Revenues in Q3

    New products are expected to deliver double-digit growth, while legacy brands are expected to offset the growth during the quarter.

    By Mike Benson
  • uploads///Invega
    Company & Industry Overviews

    How JNJ’s Invega Sustenna and Risperdal Consta Performed

    Johnson & Johnson’s (JNJ) Invega Sustenna, Xeplion, Trinza, and Trevicta combined witnessed solid growth in the third quarter.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Allergan’s Q3 2018 Estimates: Revenue Decline Expected

    Analysts are estimating that Allergan’s (AGN) third-quarter revenues will decline 3.8% to $3.88 billion.

    By Mike Benson
  • uploads///world _
    Earnings Report

    Allergan’s Q3 2018 Earnings: Analysts’ Estimates

    Allergan (AGN) is set to release its Q3 2018 earnings on October 30. Analysts estimate EPS of $4.03 on revenues of $3.88 billion.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s Stock Performance and Estimates for Q3 2018

    Wall Street analysts expect Allergan to report EPS of $3.98 on revenues of $3.8 billion in the third quarter.

    By Mike Benson
  • uploads///test _
    Healthcare

    Mergers and Acquisitions in the Pharmaceuticals Sector in Q3 2018

    On October 2, Johnson & Johnson announced the completion of the divestiture of its LifeScan business to Platinum Equity for ~$2.1 billion.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s SpotLyte and Lumivive System

    SpotLyte is the first venture from Project Moonwalker and is designed to educate consumers on medical aesthetics.

    By Mike Benson
  • uploads///Chart
    Healthcare

    A Closer Look at the Allergan–Bonti Deal

    On September 14, Allergan (AGN) announced the acquisition of Bonti Inc., a clinical-stage biotechnology company.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s Developments in September

    On September 20, Allergan (AGN) announced a partnership with actor Scott Eastwood to encourage the recognition of World Alzheimer’s Day on September 21.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What’s Eli Lilly’s Valuation as of September 27?

    Eli Lilly and Company (LLY) reported a top line of $6.4 billion in the second quarter, a 9% YoY (year-over-year) rise in revenue.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Estimates and Recommendations for Shire on September 19

    Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017.

    By Mike Benson
  • uploads///Chart  Valuation Comparison
    Company & Industry Overviews

    Pharma Stocks in Review: A Valuation Comparison

    In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

    By Mike Benson
  • uploads///Chart  EPS Growth Rate
    Company & Industry Overviews

    A Review of Pharma Stocks’ EPS Growth Rates

    In this article, we’ll compare the EPS growth rates of Eli Lilly (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

    By Mike Benson
  • uploads///Chart  ETFs
    Healthcare

    How Pharmaceutical ETFs Have Performed in 2018

    The SPDR S&P Pharmaceuticals ETF holds ~5.0% of its total investments in Eli Lilly and Company (LLY).

    By Mike Benson
  • uploads///hans reniers  unsplash
    Healthcare

    These Pharmaceutical Stocks Have Surpassed the S&P 500 in 2018

    Pharmaceutical stocks that have surpassed the S&P 500 Index’s returns YTD include Eli Lilly, Pfizer, Merck, Allergan, and GlaxoSmithKline.

    By Mike Benson
  • uploads///doctor _
    Company & Industry Overviews

    Allergan Unveils Spotlyte, Its First Digital Ventures Launch

    On September 12, Allergan (AGN) announced the launch of Spotlyte, the first launch from Project Moonwalker, the Allergan-owned digital ventures unit.

    By Mike Benson
  • uploads///bottle _
    Company & Industry Overviews

    Allergan Launches the SkinMedica Lumivive System

    On September 6, Allergan (AGN) announced the launch of its new innovative dual-acting product, the SkinMedica Lumivive System.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

    Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating investigational Lenti-D gene therapy.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Examining Amgen’s Revenue Trend in Q2 2018

    Amgen reported a 4% rise in its year-over-year revenue to ~$6.06 billion in the second quarter compared to $5.81 billion in the first quarter of 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Considering Allergan’s Q2 2018 Revenue Trend

    As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?

    Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Analysts Recommend for Bluebird Bio Stock

    As previously discussed, analysts expect Bluebird Bio (BLUE) to post revenue of $9.6 million, a net adjusted loss of ~$123.5 million, and EPS of -$2.35 in the second quarter.

    By Mike Benson
  • uploads///growth _
    Company & Industry Overviews

    FDA Approval Pushes Dermira’s Stock Price Up

    Today, Dermira (DERM) announced FDA approval for its Qbrexza™ (glycopyrronium) cloth as a treatment option for primary axillary hyperhidrosis or excessive armpit sweating in both adults and pediatric patients above nine years of age.

    By Margaret Patrick
  • uploads///dna _
    Company & Industry Overviews

    Pfizer’s EC Approval of Xeljanz for Active Psoriatic Arthritis

    Pfizer (PFE) announced in a press release yesterday that the European Commission has approved its marketing authorization application for Xeljanz in combination with methotrexate for active psoriatic arthritis.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label

    On March 19, Regeneron announced positive top line results from its Phase 3 PANORAMA trial.

    By Margaret Patrick
  • uploads///dna _
    Company & Industry Overviews

    Viking Therapeutics Stock Rose 101% on May 31

    On May 31, Viking Therapeutics (VKTX) closed at $9.99—a rise of ~101% from the previous day’s closing price of $4.97.

    By Sarah Collins
  • uploads///blood __
    Company & Industry Overviews

    No Bid Coming for Shire Reportedly

    Will Allergan buy Shire? – Apparently not CNBC saying no bid is likely.  Allergan is off its lows – only down $5 now and Shire is back to flat after being up as much as $15 (~10%) earlier. From earlier: Shire PLC (NASDAQ: SHPG) is up 4.5% as of 11:10 A.M. on Thursday following an announcement […]

    By JP Gravitt
  • uploads///Chart
    Company & Industry Overviews

    How Eli Lilly’s Endocrine Products Performed in 4Q17

    Eli Lilly and Company’s (LLY) Human Pharmaceuticals segment includes the endocrine products Humalog, Humulin, and Forteo.

    By Mike Benson
  • uploads///Ophthalmology
    Company & Industry Overviews

    How Novartis’s Ophthalmology Business Performed in 2017

    In 4Q17, Novartis’s Ophthalmology business generated revenues of $1.35 billion, which reflected ~2% growth on a year-over-year (or YoY) basis and ~2% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Sanofi’s Valuations in February 2018

    Sanofi (SNY) reported revenues of ~8.7 billion euros in 4Q17, a decline of ~2.0% in revenues compared to ~8.9 billion euros in 4Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Comparing Eli Lilly’s Post-4Q17 Valuation

    Eli Lilly’s valuation In 4Q17, Eli Lilly and Company (LLY) surpassed Wall Street analysts’ EPS (earnings per share) and revenue estimates of $1.07 and ~$5.9 billion, respectively, reporting EPS of $1.14 on revenue of ~$6.2 billion. The above chart shows Eli Lilly’s EPS and revenue since 1Q16. In fiscal 2017, Eli Lilly reported EPS of $4.28 on […]

    By Mike Benson
  • uploads///Chart
    Earnings Report

    A Look at Eli Lilly’s Neuroscience Portfolio in 4Q17

    Neuroscience portfolio Eli Lilly and Company’s (LLY) human pharmaceutical segment includes neuroscience products Cymbalta, Strattera, Prozac, and Zyprexa. Overall sales for neuroscience products fell in 4Q17 due to lower Strattera, Prozac, and Zyprexa sales, and were partially offset by strong Cymbalta sales. Cymbalta The above chart shows Eli Lilly’s neuroscience revenue since 1Q16. Cymbalta, an antidepressant drug, generated revenue […]

    By Mike Benson
  • uploads///LOE
    Company & Industry Overviews

    How Pfizer’s Peri-LOE Products Performed in 2017

    Pfizer’s (PFE) Peri-LOE products refer to those products that lost patient protection recently or are expected to lose patient protection soon.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Eli Lilly’s 4Q17 Estimates: Elanco

    Elanco is expected to report growth in revenues during 4Q17, following strong sales and a favorable impact of foreign exchange.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Pfizer’s 4Q17 Estimates: Products with Lower Sales

    In Pfizer’s (PFE) portfolio, a few of the products reported a lower sales trend due to competition from other products in the markets.

    By Mike Benson
  • uploads///Alcon
    Company & Industry Overviews

    What to Expect for Novartis’s Subsidiary Alcon in 2018

    In 1Q17, 2Q17, and 3Q17, Novartis’s (NVS) subsidiary Alcon generated revenues of $1.4 billion, $1.5 billion, and $1.5 billion, respectively.

    By Daniel Collins
  • uploads///Chart  AH
    Company & Industry Overviews

    Merck & Co.’s Animal Health Business in 3Q17

    Merck’s (MRK) Animal Health segment’s total revenues increased ~16% to $1 billion in 3Q17 compared to $865 million in 3Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Revenue Estimates for 4Q17

    Johnson & Johnson’s (JNJ) Pharmaceutical segment contributes more than 45% to total revenues. In 4Q17, it’s expected to report growth in operating revenues.

    By Mike Benson
  • uploads///article
    Fund Managers

    Why Micron Technology Was Tepper’s Top Holding in 3Q17

    Appaloosa Management was the ninth-largest investor in Micron Technology with 17 million shares as of September 30, 2017.

    By Sarah Sands
  • uploads///BL top products
    Company & Industry Overviews

    How Did Bausch + Lomb’s Top Products Perform in 3Q17?

    In 3Q17, Valeant Pharmaceuticals’ Bausch + Lomb’s Soflens generated revenues of $83 million, which was ~5% higher on a YoY basis and ~9% higher QoQ.

    By Daniel Collins
  • uploads///VTS
    Company & Industry Overviews

    Sucampo Pharmaceuticals’ Amitiza: Its Competitive Landscape

    In the branded prescription category, Amitiza competes with Ironwood Pharmaceuticals (IRWD) and Allergan’s (AGN) Linzess.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    Allergan on the Street: Analyst Recommendations This December

    As of December 6, 2017, of the 24 analysts tracking Allergan stock, 17 recommend a “buy,” while seven recommend a “hold.” None recommends a “sell.”

    By Mike Benson
  • uploads///LEP
    Company & Industry Overviews

    How Pfizer’s Premarin and Other Legacy Established Products Performed

    In 3Q17, Pfizer’s (PFE) Premarin generated revenues of $238 million, a ~2% decline on a YoY basis and a 3% decline on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Ophthalmology
    Company & Industry Overviews

    Inside Novartis’s Ophthalmology Drugs Now

    In 3Q17, Novartis’s (NVS) Lucentis generated revenues of ~$481 million, which was ~5% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).

    By Daniel Collins
  • uploads///Chart  EPS
    Earnings Report

    Allergan’s 3Q17 Earnings: Analysts’ Estimates

    Allergan (AGN) is one of the leading pharmaceutical companies, and it’s set to release its 3Q17 earnings on November 1.

    By Mike Benson
  • uploads///part  nd
    Consumer

    Healthcare Was September Loser for US Domestic Moats

    The healthcare sector has been the most challenged sector since the presidential elections in November 2016.

    By VanEck
  • uploads///Chart
    Earnings Report

    Merck’s 3Q17 Revenues Could Rise

    Analysts expect Merck’s (MRK) revenues for 3Q17 to be around $10,546 million, nearly a 0.1% increase as compared to the revenues of $10,536 million reported for 3Q16.

    By Mike Benson
  • uploads///Chart  AGN
    Healthcare

    Allergan Stock: Performance in 3Q17

    Allergan stock has fallen ~15.4% in 3Q17. It has fallen 9.8% year-to-date as of October 20, 2017.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Vabomere: Major Addition to The Medicines Company’s Portfolio?

    On August 29, 2017, the FDA approved The Medicines Company’s (MDCO) Vabomere for treating adulating patients suffering with complicated urinary tract infections.

    By Margaret Patrick
  • uploads///Lasmiditan
    Company & Industry Overviews

    What Will Help Eli Lilly Build a Stronger Migraine Portfolio?

    In September, Eli Lilly presented the results of its phase-3 Spartan trial, in which Lasmiditan demonstrated significant progress in the treatment of migraines.

    By Daniel Collins
  • uploads///Galcanezumab
    Company & Industry Overviews

    This Could Be Eli Lilly’s Long-Term Growth Driver

    In September 2017, Eli Lilly announced that a 12-month open-label study showed a positive safety and tolerability profile of Galcanezumab for migraines.

    By Daniel Collins
  • uploads///Chart  Neuro
    Company & Industry Overviews

    Quarterly Performance of Eli Lilly’s Neuroscience Products

    Strattera, a drug for attention-deficit/hyperactivity disorder, reported a 17.0% fall in revenues to $186.6 million in 2Q17 compared to $224.6 million in 2Q16.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.